OBIO
Orchestra BioMed Holdings, Inc.
NASDAQ · USHealthcareBiotechnology
$3.71+0.82%
Price as of Jul 20, 2026
OBIO financials
Orchestra BioMed Holdings, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M |
| Cost of revenue | $190.0K | $204.0K | $186.0K | $322.0K |
| Gross profit | $33.3M | $2.4M | $2.6M | $3.2M |
| Operating expenses | $85.1M | $66.7M | $54.1M | $35.9M |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M |
| Net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M |
| EBITDA | -$51.2M | -$60.7M | -$48.8M | -$33.4M |
| Basic EPS | $-1.38 | $-1.66 | $-1.48 | $-1.32 |
| Diluted EPS | $-1.38 | $-1.66 | $-1.48 | $-1.32 |
| Balance sheet | ||||
| Cash & equivalents | $34.7M | $22.3M | $30.6M | $19.8M |
| Total assets | $114.9M | $76.2M | $95.2M | $95.6M |
| Total liabilities | $51.5M | $43.2M | $27.2M | $43.0M |
| Stockholders’ equity | $63.4M | $33.0M | $68.0M | $52.5M |
| Total debt | $16.0M | $16.5M | $1.7M | $11.9M |
| Net debt | -$18.7M | -$5.7M | -$28.9M | -$7.9M |
| Cash flow | ||||
| Operating cash flow | -$49.0M | -$50.6M | -$46.1M | -$29.3M |
| Capital expenditure | -$489.0K | -$289.0K | -$78.0K | -$591.0K |
| Free cash flow | -$49.5M | -$50.8M | -$46.2M | -$29.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |